Certara Management
Management criteria checks 2/4
Certara's CEO is Jon Resnick, appointed in Jan 2026, has a tenure of less than a year. directly owns 0.023% of the company’s shares, worth $183.33K. The average tenure of the management team and the board of directors is 2.1 years and 4.4 years respectively.
Key information
Jon Resnick
Chief executive officer
n/a
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | less than a year |
| CEO ownership | 0.02% |
| Management average tenure | 2.1yrs |
| Board average tenure | 4.4yrs |
Recent management updates
Recent updates
Narrative Update • Jun 04
CERT: Biosimulation Partnerships And Model Informed Development Will Support Long Term Relevance
Analysts have reduced the Certara price target by $1.10, reflecting updated views on fair value, revenue growth, and profitability assumptions following recent research updates from several firms. Analyst Commentary Recent research updates show a broad reset in expectations around Certara, with several firms trimming price targets and reassessing how current execution lines up with prior growth assumptions.Seeking Alpha • Apr 26
Certara: An Interesting Situation To Keep Track Off
Summary Certara divested its regulatory and medical writing business for up to $135 million, shifting focus to core operations and AI-integrated drug modeling. Post-divestiture, Certara will have a net cash position and a simplified business but faces flattish growth and lingering AI disruption concerns. Valuation multiples have compressed to ~2.6x sales and ~8x EBITDA, with shares trading near all-time lows despite historical growth and a now-unleveraged balance sheet. I remain curious but cautious, given the lack of organic growth, 20x forward earnings multiple, and uncertain AI impact, despite improved financial flexibility. Read the full article on Seeking AlphaNarrative Update • Apr 25
CERT: FDA PBPK Acceptance And Biosimulation Wins Will Support Future Core Relevance
Analysts have revised Certara's fair value estimate, with the updated price target modestly lower as they incorporate reduced assumptions for revenue growth and profit margins, along with a substantially higher expected future P/E multiple. Analyst Commentary Recent Street research on Certara has turned more cautious, with multiple firms cutting price targets and several moving to more neutral ratings.Narrative Update • Apr 07
CERT: Biosimulation And FDA Modeling Wins Will Underpin Future Core Relevance
Narrative Update on Certara The analyst price target on Certara has shifted lower, with several firms moving their targets into the $8 to $10 range. This reflects concerns around a Q4 services miss, slower software bookings, updated 2026 guidance, and a perceived need for greater investment to support core growth.Narrative Update • Mar 23
CERT: Biosimulation Leadership And FDA Modeling Wins Will Support Future Relevance
Analysts trimmed their fair value estimate for Certara from $9.60 to $9.19 per share, citing lower price targets across the Street, more conservative assumptions for revenue growth and valuation multiples, and ongoing questions around execution after recent guidance and services softness. Analyst Commentary Street research around Certara has turned more cautious overall, with several firms reducing price targets and, in some cases, ratings.Narrative Update • Mar 09
CERT: Biosimulation Leadership And FDA Use Of Modeling Will Support Shares
The analyst price target for Certara has been reduced by $2.77 to $9.60 as analysts factor in softer Q4 services results, slower software bookings, a more cautious 2026 outlook, and increased uncertainty around the pace of core growth despite the company’s position in model informed drug development. Analyst Commentary Recent research has turned more cautious on Certara, with a series of target cuts and rating changes following Q4 results, updated 2026 guidance, and ongoing questions around core growth and execution.Narrative Update • Feb 23
CERT: Biosimulation Leadership And New CEO Appointment Will Support Shares
Analysts have trimmed their average price target for Certara by $1 to $12, reflecting slightly higher discount rate assumptions and modestly lower future P/E expectations, even as they continue to highlight the company as a leader in biosimulation with what they view as an improving demand backdrop. Analyst Commentary Recent Street research paints a mixed picture for Certara, with some analysts focusing on long term growth drivers in biosimulation and others flagging near term execution and valuation questions.Analysis Article • Feb 12
Certara, Inc.'s (NASDAQ:CERT) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
Certara, Inc. ( NASDAQ:CERT ) shares have had a horrible month, losing 26% after a relatively good period beforehand...Narrative Update • Feb 08
CERT: Biosimulation Expansion And New CEO Hire Will Support Shares
Analysts have trimmed their average price target on Certara to about $12, down from roughly $13. This reflects a mix of caution around competition and regulatory pressure, as well as continued confidence in the company's position in biosimulation and its potential to expand further into early stage drug development.Narrative Update • Jan 25
CERT: Biosimulation Leadership And New CEO Transition Should Support Shares Recovery
Analysts have trimmed their price expectations for Certara, with the consensus target easing by about $1 to reflect slightly lower valuation multiples tied to competition, regulatory questions, softer services bookings, and leadership changes, while still highlighting the company's position in biosimulation and potential benefits from acquisitions such as Chemaxon. Analyst Commentary Recent research on Certara points to a mixed but generally constructive tone, with analysts balancing confidence in the core biosimulation franchise against execution risks in services, competition, and regulatory questions.Narrative Update • Jan 10
CERT: Biosimulation Expansion And New CEO Should Support Shares Rebound
Analysts have trimmed their average price target on Certara by about $0.17 to roughly $12.38. This reflects recent cuts to some individual targets alongside continued recognition of the company as a leader in biosimulation and expectations that prior stock weakness tied to bookings, biopharma budget timing, and leadership changes may have been overdone.Narrative Update • Dec 18
CERT: Shares Will Benefit From Biosimulation Expansion As Pharma Rebound Unfolds
Analysts have modestly trimmed their blended price target on Certara from $13.21 to $12.54 per share, reflecting slightly lower growth and valuation assumptions, even as they highlight the company’s leadership in biosimulation and long term opportunity in modernizing drug development. Analyst Commentary Street research remains mixed on Certara, with most analysts recognizing the company’s strategic positioning in biosimulation and drug development modernization, while diverging on the pace of execution and appropriate valuation.Analysis Article • Dec 08
Does Certara (NASDAQ:CERT) Have A Healthy Balance Sheet?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...Narrative Update • Dec 04
CERT: Shares Will Benefit From Biosimulation Leadership As Pharma Rebound Emerges
The analyst price target for Certara has been modestly reduced from $13.50 to about $13.21, as analysts balance near term headwinds in services bookings with growing confidence in the company’s leadership in biosimulation and its longer term role in modernizing drug development. Analyst Commentary Recent research updates reflect a generally constructive but selective stance on Certara, with views splitting between enthusiasm for its strategic position in biosimulation and caution around execution risk and near term bookings softness.Narrative Update • Nov 20
CERT: Shares Will Benefit From Pharma Rebound And Drug Development Modernization
Analysts have reduced Certara's fair value price target from $14.75 to $13.50, citing revised growth expectations, softer profit margins, and a need for clearer evidence of traction in core initiatives. Analyst Commentary Recent analyst research highlights a range of perspectives on Certara, with differing views on both its near-term prospects and longer-term potential within the drug development sector.Narrative Update • Nov 06
CERT: Shares Poised To Gain From Pharma And Biotech Sector Rebound Ahead
Analyst Price Target Update for Certara Analysts have maintained their price target for Certara at $14.75 per share, citing the company's strong positioning in the anticipated pharma and biotech rebound as well as an attractive current valuation relative to its long-term prospects. Analyst Commentary Analyst perspectives on Certara highlight a mix of optimism and caution as the company positions itself within a strengthening pharmaceutical and biotechnology sector.Narrative Update • Oct 23
Analysts Maintain Certara Price Target as Pharma Sector Recovery and New Developments Drive Outlook
Analysts have maintained their price target for Certara at $14.75, citing the company’s positioning at the center of a recovering pharma and biotech sector as a key reason for their continued positive outlook. Analyst Commentary Bullish Takeaways Bullish analysts highlight Certara's central position in the anticipated rebound of the pharma and biotech sectors.Narrative Update • Oct 08
EMA Approval And AI Integration Will Drive Biosimulation Despite Risks
Certara's analyst price target has increased from $14.11 to $14.75. This change reflects analysts' optimism about the company's strategic position in the pharma sector and its potential to benefit from growing R&D investment trends.Analysis Article • Oct 07
Subdued Growth No Barrier To Certara, Inc. (NASDAQ:CERT) With Shares Advancing 28%
Certara, Inc. ( NASDAQ:CERT ) shares have had a really impressive month, gaining 28% after a shaky period beforehand...Analysis Article • Sep 04
A Look At The Fair Value Of Certara, Inc. (NASDAQ:CERT)
Key Insights Certara's estimated fair value is US$11.21 based on 2 Stage Free Cash Flow to Equity Certara's US$10.50...Analysis Article • Aug 14
Shareholders Will Be Pleased With The Quality of Certara's (NASDAQ:CERT) Earnings
NasdaqGS:CERT 1 Year Share Price vs Fair Value Explore Certara's Fair Values from the Community and select yours When...Narrative Update • Aug 08
EMA Approval And AI Integration Will Drive Biosimulation Despite Risks
The slight downward revision in Certara’s price target reflects a modest reduction in its future P/E ratio, while revenue growth expectations remain essentially unchanged, resulting in a new consensus price target of $14.11. What's in the News Certara reiterated full-year 2025 revenue guidance of $415 million to $425 million.Analysis Article • Aug 08
Some Investors May Be Worried About Certara's (NASDAQ:CERT) Returns On Capital
NasdaqGS:CERT 1 Year Share Price vs Fair Value Explore Certara's Fair Values from the Community and select yours If we...Analysis Article • Jul 18
Risks To Shareholder Returns Are Elevated At These Prices For Certara, Inc. (NASDAQ:CERT)
Certara, Inc.'s ( NASDAQ:CERT ) price-to-sales (or "P/S") ratio of 4.3x may not look like an appealing investment...Analysis Article • Jun 27
Is Certara (NASDAQ:CERT) Using Too Much Debt?
David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...New Narrative • Jun 08
FDA Phaseout And AI Integration Will Expand Biosimulation Demand
Regulatory shifts and long-term outsourcing trends are boosting demand for Certara's biosimulation and data-driven modeling solutions, supporting recurring revenue growth and market expansion.Analysis Article • May 07
Certara (NASDAQ:CERT) Will Be Hoping To Turn Its Returns On Capital Around
To find a multi-bagger stock, what are the underlying trends we should look for in a business? Firstly, we'll want to...Analysis Article • Apr 15
Certara, Inc.'s (NASDAQ:CERT) 32% Price Boost Is Out Of Tune With Revenues
Certara, Inc. ( NASDAQ:CERT ) shareholders have had their patience rewarded with a 32% share price jump in the last...Seeking Alpha • Apr 11
Buy Certara After The FDA Announcement
Summary The FDA's phase-out of animal testing for monoclonal antibody therapies boosts Certara's growth prospects, as evidenced by a 15% stock jump. Certara's recently posted a 14.1% revenue increase Y/Y, with significant contributions from biosimulation and Chemaxon businesses. Certara's cautious AI investments align with the FDA's regulatory changes, enhancing its end-to-end biosimulation offerings from drug discovery to clinical trials. Certara's 2025 revenue forecast is $415-$425 million, with an EBITDA margin of 30-32%, making CERT stock an attractive speculative buy. Read the full article on Seeking AlphaAnalysis Article • Mar 29
Why Certara, Inc. (NASDAQ:CERT) Could Be Worth Watching
While Certara, Inc. ( NASDAQ:CERT ) might not have the largest market cap around , it saw significant share price...Analysis Article • Feb 27
Here's Why Certara (NASDAQ:CERT) Can Manage Its Debt Responsibly
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Jan 11
Certara, Inc.'s (NASDAQ:CERT) Share Price Not Quite Adding Up
When close to half the companies in the Healthcare Services industry in the United States have price-to-sales ratios...Analysis Article • Dec 19
Is Certara, Inc. (NASDAQ:CERT) Worth US$10.9 Based On Its Intrinsic Value?
Key Insights Certara's estimated fair value is US$8.10 based on 2 Stage Free Cash Flow to Equity Certara is estimated...Analysis Article • Nov 15
Certara (NASDAQ:CERT) Is Reinvesting At Lower Rates Of Return
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Typically, we'll...Analysis Article • Oct 24
Is Certara, Inc. (NASDAQ:CERT) Potentially Undervalued?
Certara, Inc. ( NASDAQ:CERT ), is not the largest company out there, but it saw significant share price movement during...CEO
Jon Resnick (53 yo)
less than a year
Tenure
Mr. Jon Resnick is CEO & Director of Certara, Inc. from January 1, 2026. He had been President of United States & Canada at IQVIA Holdings Inc. (formerly known as Quintiles IMS Holdings, Inc.) since 2019 a...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President & Chief Commercial Officer | 2.8yrs | US$1.89m | 0.071% $ 570.0k | |
| SVP, Principal Accounting Officer & Chief Financial Officer | 3.2yrs | US$2.72m | 0.061% $ 494.1k | |
| President of Certara Predictive Technologies | 6.4yrs | US$2.03m | 0.21% $ 1.7m | |
| President of Drug Development Solutions | 1.3yrs | US$1.93m | 0.0053% $ 42.5k | |
| CEO & Director | less than a year | no data | 0.023% $ 183.3k | |
| Chief Technology Officer & Chief AI Officer | less than a year | no data | no data | |
| Senior VP | 2.1yrs | no data | 0.021% $ 166.0k | |
| Senior Vice President of Corporate Development | no data | no data | no data | |
| Chief Marketing Officer | 3yrs | no data | no data | |
| Chief Human Resources Officer | 2.1yrs | no data | 0.011% $ 86.9k | |
| President of Certara Data Sciences | 1yr | no data | no data |
2.1yrs
Average Tenure
56.5yo
Average Age
Experienced Management: CERT's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Director | less than a year | no data | 0.023% $ 183.3k | |
| Independent Director | 13.4yrs | no data | 0.027% $ 217.6k | |
| Independent Chairman of the Board | 8.1yrs | US$313.51k | 0.31% $ 2.5m | |
| Independent Director | 5.8yrs | US$246.01k | 0.14% $ 1.1m | |
| Independent Director | 3.9yrs | US$246.01k | 0.033% $ 262.7k | |
| Independent Director | 1.7yrs | US$236.01k | 0.017% $ 137.1k | |
| Independent Director | 3.5yrs | no data | no data | |
| Independent Director | 4.8yrs | US$246.01k | 0.033% $ 268.6k | |
| Senior Consultant & Member of Simcyp Scientific Advisor Board | 7.2yrs | no data | no data | |
| Independent Director | less than a year | no data | 0% $ 0 |
4.4yrs
Average Tenure
66yo
Average Age
Experienced Board: CERT's board of directors are considered experienced (4.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/10 13:26 |
| End of Day Share Price | 2026/06/10 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Certara, Inc. is covered by 18 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joseph Vruwink | Baird |
| Luke Sergott | Barclays |
| Sean Dodge | BMO Capital Markets Equity Research |